Skip to Main Content

WASHINGTON — A proposed version of drug pricing legislation circulating among Capitol Hill aides and lobbyists includes an expansive carveout for small biotechnology companies and significantly waters down a provision to let Medicare negotiate drug prices, according to a draft obtained by STAT.

The new compromise would only allow the health secretary to negotiate the price of drugs that are manufactured by a single company that have outlasted their initial exclusivity periods granted by the Food and Drug Administration. The number of negotiation-eligible drugs would be small, too: 10 medicines beginning in 2025, with a gradual increase to 30 by 2028. Insulin products would also be eligible.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment